Metastatic Squamous Neck Cancer With Occult Primary - 25 Studies Found
Recruiting |
: SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes : Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma : 2015-12-07 : Drug: SF1126 |
Completed |
: Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer :
|
Active, not recruiting |
: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck :
|
Active, not recruiting |
: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer :
|
Completed |
: Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab :
|
Terminated |
: Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck :
|
Completed |
: S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer :
|
Completed |
: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer :
|
Completed |
: Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer :
|
Active, not recruiting |
: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer :
|